Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma

Journal of Clinical Pathology

Volumn 65, Issue 6, 2012, Pages 522-527

  Enomoto, Yasunori ^a   Kasai, Takahiko ^a   Takeda, Maiko ^a   Takano, Masato ^a   Morita, Kohei ^a   Kadota, Eiji ^b   Iizuka, Norishige ^b   Maruyama, Hiroshi ^c   Haratake, Joji ^d   Kojima, Yu ^e   Ikeda, Naoya ^e   Inatsugi, Naoki ^f   Nonomura, Akitaka ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kishiwada City Hospital   (Japan)

^c HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

^d Saiseikai Yahata General Hospital   (Japan)

^e NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f Kenseikai Dongo Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; LUNG NON SMALL CELL CANCER; MALE; MISSENSE MUTATION; MULTIPLE MYELOMA; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MESOTHELIOMA; MIDDLE AGED; MUTATION, MISSENSE; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861798901     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200631     Document Type: Article

References (26)

1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72. (Pubitemid 29046253)
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-18.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. (Pubitemid 46606305)
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
5. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
6. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82.
7. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501. (Pubitemid 44799723)
8. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
9. Rena O, Boldorini LR, Gaudino E, et al. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol 2011;104:701-5.
10. Okuda K, Sasaki H, Kawano O, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008;134:1105-11.
11. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-81. (Pubitemid 41646604)
12. Enomoto Y, Kasai T, Takeda M, et al. A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. Pathol Int 2012;62:226-31.
13. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int 2010;60:395-9.
14. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807. (Pubitemid 46606235)
15. Martin V, Mazzucchelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009;62:314-24.
16. Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011;13:R35.
17. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17. (Pubitemid 34163530)
18. Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGFR with histology and survival using fixed paraffin-embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924-6. (Pubitemid 20197007)
19. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 2006;51:207-15. (Pubitemid 43144364)
20. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15.
21. Edwards JG, Swinson DE, Jones JL, et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006;54:399-407. (Pubitemid 44634142)
22. Govindan R, Kratzke RA, Herndon JE 2nd, et al; Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300-4. (Pubitemid 40490190)
23. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005;50:375-84.
24. Foster JM, Radhakrishna U, Govindarajan V, et al. Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. World J Surg Oncol 2010;8:88.
25. Foster JM, Gatalica Z, Lilleberg S, et al. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. Ann Surg Oncol 2009;16:152-8.
26. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-8.